Evidence map›Paper›PMID 38974750›Full record

ArticleJournal of obstetrics and gynaecology of India2024

Cancer Stem Cells (CD44

Unedo Hence Markus Sihombing, Andrijono Andrijono, Gatot Purwoto, Supriadi Gandamihardja, Alida R Harahap, Primariadewi Rustamadji, Aria Kekalih, Retno Widyawati, Dzicky Rifqi Fuady

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of obstetrics and gynaecology of India, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Unedo Hence Markus SihombingGynecologic-Oncology Division, Department of Obstetrics and Gynecology, Tarakan Hospital, Jakarta, Indonesia.ORCID 0000-0002-3671-2400
Andrijono AndrijonoGynecologic-Oncology Division, Department of Obstetrics and Gynecology, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
Gatot PurwotoGynecologic-Oncology Division, Department of Obstetrics and Gynecology, Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
Supriadi GandamihardjaGynecologic-Oncology Division, Department of Obstetrics and Gynecology, Hasan Sadikin Hospital, Universitas Padjadjaran, Bandung, Indonesia.
Alida R HarahapDepartment of Clinical Pathology, Faculty of Medicine, Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
Primariadewi RustamadjiDepartment of Anatomic Pathology, Faculty of Medicine, Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
Aria KekalihOccupational Medicine Division, Community Medicine Department, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
Retno WidyawatiDepartment of Anatomic Pathology, Faculty of Medicine, Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
Dzicky Rifqi FuadyGynecologic-Oncology Division, Department of Obstetrics and Gynecology, Tarakan Hospital, Jakarta, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Backgrounds: Ovarian cancer is a deadly women cancer with many chemoresistance after standard treatment. Ovarian cancer tissues' CD44 Materials and Methods: We conducted a cohort study of 64 patients divided into two groups (32 patients in each group) at the Cipto Mangunkusumo, Tarakan, Dharmais, and Fatmawati Hospital which are located in Jakarta city, Indonesia. The patients underwent cytoreductive debulking and histopathological examination continued by six series of chemotherapy followed by six months of observation. We divided the groups into chemoresistant and chemosensitive by using Response Criteria in Solid Tumors (RECIST) criteria. Ovarian cancer tissue immunohistochemistry tests were then performed to count the CSCs, RAD6 and DDB2 expressions. Results: We found relationship between increased CSCs, RAD6 and reduced DDB2 ( Conclusions: The conclusion is that CSCs, RAD6 and DDB2 expressions are significantly associated with ovarian cancer chemoresistance, and IHC-UNEDO scoring should be considered as a tool to predict ovarian cancer chemoresistance.

Indexed as

ChemoresistanceCSCsImmunohistochemistryOvarian cancerScoring

Identifiers

PMID38974750
PMCPMC11224164

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.